CareDx
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 4 days.
- Recent price momentum is +196.6% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 13.7% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation F
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 29.5x | Better than 23% |
| Forward P/E | 141.7x | Better than 2% |
| Price / Sales | 8.2x | Better than 13% |
| P/E vs own 5-yr range | 99th pctl | Better than 5% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability C
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 67.6% | Better than 81% |
| Operating margin | -6.6% | Better than 16% |
| Net margin | -5.6% | Better than 19% |
| Return on equity | -6.3% | Better than 22% |
| Return on invested capital | -7.7% | Better than 19% |
Momentum A+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 44.0% | Better than 99% |
| 6-month return | 223.6% | Better than 100% |
| 12-month return (ex latest month) | 302.9% | Better than 100% |
| Distance below 52-week high | 23.0% | Better than 54% |
Financial Health B
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.9x | Better than 71% |
| Debt to assets | 6.3% | Better than 76% |
| Free cash flow / net income | 60.1% | Better than 17% |
Analyst View B-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 75.0% | Better than 51% |
| Upside to average target | 32.1% | Better than 51% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 71.92
- Open
- 70.56
- Day range
- 69.26 - 72.94
- Avg price
- 70.36
- Volume
- 782.02K
- Turnover
- 55.02M
- Turnover ratei
- 1.54%
- Volume ratioi
- 0.98
- Amplitudei
- 5.12%
- 52-week rangei
- 15.56 - 90.87
Valuation
- P/Ei
- -175.00
- P/E (TTM)i
- 29.54
- P/Bi
- 7.87
- EPSi
- -0.40
- Book value / shi
- 8.90
- Net profit
- -21.02M
- Net assets
- 467.47M
Share structure
- Market cap
- 3.68B
- Float capi
- 3.56B
- Shares out
- 52.54M
- Float sharesi
- 50.82M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
23.0% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-7.03M net over the window
Short interest
- Shares short
- 7.19M
- % of floati
- 13.68%
- Days to coveri
- 5.28
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of CareDx (CDNA)?
CareDx last traded at 70.00. This page shows a periodic quote snapshot. Check the displayed quote time.
What is CareDx's market cap?
About 3.68B.
What is the P/E ratio of CareDx?
The trailing twelve-month P/E is 29.54. The Valuation tab shows it against the stock's own five-year range.
Does CareDx pay a dividend?
CareDx does not currently pay a regular dividend.
Is CareDx a buy according to analysts?
The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 92.50, which implies 32.1% upside from the current price. This is not investment advice.
What is CareDx's StockVane Quant Rating?
The StockVane Momentum strategy currently rates CareDx a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:02:25 · For reference only, not investment advice and not tailored to your situation.
CareDx discussion 0 comments